Platform biology and the evidence, manufacturing and access demands of genetic medicines.
A durable therapy changes more than a treatment schedule. It asks healthcare to think differently about follow-up, evidence, payment, and the years that come after.
Follow the decisions between a promising result and completed care—and distinguish scientific failure from avoidable execution gaps.
A fictional day asks what earlier detection, personalized treatment, and connected care would need to deliver for a real person.
Genzyme’s remediation history anchors a hypothetical outage-exposure and backup-capacity decision.
Kymriah and current cell-therapy commercialization frame manufacturing reliability, release timing and patient readiness.
The Elevidys safety revision informs a hypothetical surveillance budget and an eligibility-sensitive operating plan.
![CLARITY AD: 18-month CDR-SB change. Lecanemab: 1.21; Placebo: 1.66. CDR-SB points. Reported trial values [1]; greater increase indicates greater worsening.](/images/consulting/external-controls-neurology-evidence-reserve-record.svg)
Leqembi’s randomized evidence and AMT-130’s September update frame a client’s sensitivity analysis and evidence reserve.
![IRIS: major cytogenetic response at 18 months. Imatinib: 87.1; Comparator: 34.7. Response (%). Historical randomized trial [1]; not survival or a forecast.](/images/consulting/imatinib-target-validation-capital-gate-record.svg)
IRIS and a recent biomarker-led approval frame a hypothetical oncology program’s recruitment, assay and capital decisions.
Why a small, well-defined population still needs rigorous comparison, diagnostic execution and a clear financing plan.
Two randomized trials illustrate how to communicate a strong biomarker result without extending it beyond the measured outcome.
HERALD and the 2021 rolling-review withdrawal illustrate a portfolio decision after an incomplete success.
A historical storage change shows why a process convenience needs product-specific supporting data.
APOLLO joined a molecular mechanism to 18-month clinical measures in a defined hereditary disease.
The CMS access model makes outcome contracting, treatment logistics, and follow-up separate milestones.